Physician profile
Khyber Khan
NPI 1902113699
$2,523.66
in general payments reported to CMS, 2019-2025
28 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $230 · 2021: $603 · 2022: $683 · 2023: $394 · 2024: $33.94 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $521.46 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $310.86 | 2019-2025 | |
| Gilead Sciences, INC. | $279.64 | 2020-2023 | |
| Novo Nordisk INC | $276.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $148.40 | 2021-2025 | Freestyle Libre 3, Amplatzer Talisman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.66 | 2020 | |
| Renalytix Ai, INC. | $80.13 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $73.55 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $70.78 | 2021-2022 | |
| Pfizer INC. | $56.62 | 2019-2025 | |
| Lilly USA, LLC | $56.53 | 2021-2025 | Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.16 | 2020-2021 | |
| Edwards Lifesciences Corporation | $44.85 | 2023-2024 | |
| Amarin Pharma, INC. | $43.83 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.92 | 2020 | |
| Merck Sharp & Dohme LLC | $36.57 | 2019-2025 | Capvaxive, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $33.22 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.60 | 2025 | |
| Currax Pharmaceuticals LLC | $29.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.16 | 2019-2021 | |
| Sanofi Pasteur INC. | $26.62 | 2022 | |
| Eisai INC. | $24.66 | 2021 | |
| Horizon Therapeutics Plc | $21.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2022 | |
| Exact Sciences Corporation | $19.82 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $17.75 | 2019 | |
| Boston Scientific Corporation | $15.33 | 2025 | General - Pain Management |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khyber Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.